
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is positioned favorably because its core R&DS franchise is showing durable momentum, with 3Q net new bookings of $3.2 bln, a 1.2x book-to-bill, and five consecutive quarters of healthy LTM bookings that support visibility into 2027. The company also appears to be exiting a period of industry-wide disruption, as large-pharma re-procurement has largely reset relationships and demand indicators such as EBP funding, RFP flow, and win rates are improving, while Commercial Solutions remains stable despite temporary 3Q volatility. Management’s raised 2026 adjusted EPS guide of $12.90-$13.00, expected margin expansion, and AI-driven productivity gains further reinforce the view that the business can convert improving demand into stronger earnings and cash generation.
Bears say
IQVIA Holdings is exposed to several fundamental pressures that weaken its outlook, including AI disruption, FX variances, and an uncertain funding environment that could reduce demand for clinical research and commercialization services. The company also faces risk from any slowdown in pharma spending, delays in planned clinical trial starts, and regulatory changes that could disrupt the drug development process and pressure its outsourced trial and analytics franchise. In addition, higher-than-industry-average leverage, the need for timely retirement of matured debt, and M&A execution risk raise financing and execution concerns, while deteriorating biotech VC funding and biopharma consolidation could further compress growth visibility.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About IQVIA Hlds (IQV) Forecast
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares